1.
Whitaker
Raymond Whitaker has been a General Partner of EuclidSR Partners, L.P. since its inception in January 2000. He began venture investing full-time as Vice ...
2.
Smith
Leon G. Smith, M.D. University of Medicine and Dentistry of New Jersey. Dr. Smith is currently Professor of Medicine and of Preventive Medicine / Community ...
3.
Mott
David M. Mott General Partner, New Enterprise Associates. David Mott joined New Enterprise Associates (N.E.A.) in September 2008 as a General Partner ...
4.
Release 2005 10 05
Rib-X Pharmaceuticals, Inc. Granted Key Antibiotic Drug Discovery Patents ... based drug design approaches to efficiently design new classes of antibiotics ...
5.
Rib-X Pharmaceuticals Inc.
Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, ...
6.
Rib-X Pharmaceuticals Inc.
Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, ...
7.
Rib-X Pharmaceuticals Inc.
Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, ...
8.
Rib-X Pharmaceuticals Inc.
Structure-based drug design start-up, specializing in the ribosome as a target, and bacterial antibiotic resistance. Includes mechanisms of action, ...
9.
Wenzel
Richard P. Wenzel, M.D., M.Sc. Virginia Commonwealth University. Dr. Wenzel is author of more than 480 publications, the editor of six textbooks and the ...
10.
Wenzel
Richard P. Wenzel, M.D., M.Sc. Virginia Commonwealth University. Dr. Wenzel is author of more than 480 publications, the editor of six textbooks and the ...
